Projection of Long-Term Visual Acuity Outcomes Based on Initial Treatment Response in Neovascular Age-Related Macular Degeneration

Ophthalmology
Vuong NguyenFight Retinal Blindness! Study Group

Abstract

To explore various methods for assessing the early response to vascular endothelial growth factor (VEGF) inhibitors for neovascular age-related macular degeneration and investigate their association with 3-year visual acuity (VA) outcomes. Database study, prospectively designed. Treatment-naïve eyes in the Fight Retinal Blindness! registry that commenced anti-VEGF therapy between January 1, 2007, and March 1, 2014, that received 3 anti-VEGF injections within the first 3 months. The early response was defined as occurring up until the fourth injection. Various early response metrics were explored: (1) achieving good VA (≥70 letters; Snellen equivalent, 20/40), (2) absolute change in VA from baseline, (3) time to first grading of the choroidal neovascular lesion as inactive, and (4) maximum rate of VA change between successive injections. Proportion of eyes achieving ≥70 letters 3 years. This study included 2051 treatment-naïve eyes from 1828 patients. Achieving good vision at 3 years was associated significantly with (1) having good vision by the fourth injection (VA ≥70 vs. VA <70 letters: odds ratio [OR], 9.8; 95% confidence interval [CI], 6.5-14.7), (2) small (1-5 letters) or large (>5 letters) early VA gains (vs. early VA lo...Continue Reading

References

Oct 6, 2006·The New England Journal of Medicine·Philip J RosenfeldUNKNOWN MARINA Study Group
Feb 3, 2007·Ophthalmology·David S BoyerUNKNOWN MARINA Study Group
Oct 11, 2012·Ophthalmology·Gui-shuang YingUNKNOWN Comparison of Age-related Macular Degeneration Treatments Trials Research Group
Jan 23, 2013·Ophthalmology·Stephanie A HagstromUNKNOWN Comparison of AMD Treatments Trials Research Group
Dec 18, 2013·Survey of Ophthalmology·Robert P FingerRobyn H Guymer
Mar 22, 2014·JAMA Ophthalmology·Stephanie A HagstromUNKNOWN Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) Research Group
Sep 25, 2014·The British Journal of Ophthalmology·Daniel BarthelmesUNKNOWN Fight Retinal Blindness! Project Investigators
Apr 8, 2015·Ophthalmology·Jennifer J ArnoldUNKNOWN Fight Retinal Blindness Study Group
Jun 23, 2015·Ophthalmology·Mark C GilliesUNKNOWN Fight Retinal Blindness Study Group
Sep 19, 2015·Ophthalmology·Gui-Shuang YingUNKNOWN Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) Research Group
Mar 20, 2016·The British Journal of Ophthalmology·Daniel BarthelmesUNKNOWN Fight Retinal Blindness! Project Investigators
May 2, 2016·American Journal of Ophthalmology·Ian A RodriguesMark C Gillies
May 10, 2016·Ophthalmology·UNKNOWN Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research GroupStuart L Fine

❮ Previous
Next ❯

Citations

Mar 15, 2020·Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft·Nicole EterFocke Ziemssen
May 29, 2020·Clinical & Experimental Ophthalmology·Shaan WiryasaputraMark C Gillies
Jan 30, 2020·Scientific Reports·Yan GaoChui Ming Gemmy Cheung
Jun 24, 2020·Graefe's Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Für Klinische Und Experimentelle Ophthalmologie·Christoph EhlkenAlexander K Schuster
Feb 3, 2021·Graefe's Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Für Klinische Und Experimentelle Ophthalmologie·Justus G Garweg, Christin Gerhardt

❮ Previous
Next ❯

Related Concepts

Related Feeds

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.